For US residents only.

Understanding Treatment

TAFINLAR + MEKINIST

Patient

Patients with BRAF mutations have the option of taking targeted therapies, such as BRAF and MEK inhibitors, which are designed to target cells with the BRAF gene mutation and treat this form of advanced melanoma. These targeted therapies are intended to work by blocking the action of certain proteins associated with the BRAF gene so that they inhibit the faulty signals that can lead to the growing and spreading of cancer cells such as melanoma. Targeted therapy can also affect healthy cells.

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) combination therapy targets 2 different points in a pathway that sends signals in cells. Although TAFINLAR + MEKINIST combination therapy has been studied in patients who have advanced melanoma with a mutated BRAF gene, the way that TAFINLAR + MEKINIST combination therapy works has only been shown in laboratory studies. Medical research has shown that TAFINLAR + MEKINIST combination therapy can slow the growth of certain melanoma cancer cells that have an abnormal BRAF gene.

TAFINLAR + MEKINIST combination therapy can be used to treat people with a type of advanced melanoma:

  • that has spread to other parts of the body (for example, the liver, lungs, and brain) or cannot be removed by surgery, and
  • that has a certain type of abnormal BRAF (V600E or V600K mutation–positive) gene as determined by an FDA-approved test

 

It is important to keep an open dialogue with your doctor. This will help you have more productive conversations so you can get the most out of your TAFINLAR + MEKINIST combination therapy.